The aim of my research is to combine different biomarkers looking at patterns of disease. Due to the complexity and heterogeneity of Alzheimer’s disease (AD) and other neurodegenerative disorder, using one biomarker is probably not enough. The focus of my research has long been on structural magnetic resonance imaging investigating patterns of atrophy, but my research extends to other imaging modalities such as MR-spectroscopy, resting state fMRI, MR-diffusion, positron emission tomography (PET) and computer tomography (CT) etc. Further, the combination of neuroimaging biomarkers with CSF and blood markers is of great interest. The need for advanced statistical tools is important when combing large amounts of data from multiple neuroimaging modalities. Combining multiple biomarkers with multivariate tools will hopefully aid in diagnosing the disease in an early stage which is important when effective treatments for AD can be administered, monitor disease progression, target the right population for clinical trial and understand the underlying mechanisms of different diseases.